2seventy bio (2seventy bio) Cyclically Adjusted PS Ratio : (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Cyclically Adjusted PS Ratio?

2seventy bio does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

2seventy bio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for 2seventy bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Cyclically Adjusted PS Ratio Chart

2seventy bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cyclically Adjusted PS Ratio

Get a 7-Day Free Trial

2seventy bio Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of 2seventy bio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, 2seventy bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2seventy bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Cyclically Adjusted PS Ratio falls into.

2seventy bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

2seventy bio does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

2seventy bio (NAS:TSVT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

2seventy bio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio (2seventy bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.2seventybio.com

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Executives

Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory	officer: Chief Scientific Officer	POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Lin Wei	director	C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron	officer: Chief Operating Officer	2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus	director	16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch	director
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938